Next Article in Journal / Special Issue
Study of Protein Phosphatase 2A (PP2A) Activity in LPS-Induced Tolerance Using Fluorescence-Based and Immunoprecipitation-Aided Methodology
Previous Article in Journal
Bacterial Sigma Factors and Anti-Sigma Factors: Structure, Function and Distribution
Previous Article in Special Issue
Transcriptional Regulation of Chemokine Genes: A Link to Pancreatic Islet Inflammation?
Article Menu

Export Article

Open AccessReview
Biomolecules 2015, 5(3), 1266-1283; doi:10.3390/biom5031266

NF-kappaB Signaling in Chronic Inflammatory Airway Disease

Lung Health Research Centre (LHRC), Department Pharmacology and Therapeutics, University of Melbourne, Grattan St., Parkville 3010, Victoria, Australia
Academic Editor: Ivana Vancurova
Received: 28 April 2015 / Revised: 31 May 2015 / Accepted: 4 June 2015 / Published: 26 June 2015
(This article belongs to the Special Issue Transcriptional Regulation of Pro-Inflammatory Genes)
View Full-Text   |   Download PDF [274 KB, uploaded 26 June 2015]   |  

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are obstructive airway disorders which differ in their underlying causes and phenotypes but overlap in patterns of pharmacological treatments. In both asthma and COPD, oxidative stress contributes to airway inflammation by inducing inflammatory gene expression. The redox-sensitive transcription factor, nuclear factor (NF)-kappaB (NF-κB), is an important participant in a broad spectrum of inflammatory networks that regulate cytokine activity in airway pathology. The anti-inflammatory actions of glucocorticoids (GCs), a mainstay treatment for asthma, involve inhibition of NF-κB induced gene transcription. Ligand bound GC receptors (GRs) bind NF-κB to suppress the transcription of NF-κB responsive genes (i.e., transrepression). However, in severe asthma and COPD, the transrepression of NF-κB by GCs is negated as a consequence of post-translational changes to GR and histones involved in chromatin remodeling. Therapeutics which target NF-κB activation, including inhibitors of IκB kinases (IKKs) are potential treatments for asthma and COPD. Furthermore, reversing GR/histone acetylation shows promise as a strategy to treat steroid refractory airway disease by augmenting NF-κB transrepression. This review examines NF-κB signaling in airway inflammation and its potential as target for treatment of asthma and COPD. View Full-Text
Keywords: airway smooth muscle; allergic asthma; alveolar macrophages; cigarette smoke; eosinophils; epithelium; emphysema; histone deacetylase; phosphoinositide 3 kinase-delta (PI3K-δ); sirtuins airway smooth muscle; allergic asthma; alveolar macrophages; cigarette smoke; eosinophils; epithelium; emphysema; histone deacetylase; phosphoinositide 3 kinase-delta (PI3K-δ); sirtuins
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schuliga, M. NF-kappaB Signaling in Chronic Inflammatory Airway Disease. Biomolecules 2015, 5, 1266-1283.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top